UCB congratulates Kerry Black, Head of Early Solutions U.S. Operations, and Brooke Fleming, Head of Omnichannel Marketing and Digital Enablement, for their recognition by the Healthcare Businesswomen's Association (HBA) as 2022 Luminary and Rising Star, respectively. 

Last year, UCB launched its Voices on Value blog series to foster a dialogue around how to make our health system better, stronger, and more accessible now and in the future. To advance this dialogue, UCB is releasing its first-ever U.S. Sustainable Access and Pricing Transparency Report, which underscores UCB’s commitment to an innovative, competitive, and value-based system. 

At UCB, our aim is to amplify the power of scientific innovation through digital transformation, ensuring we deliver the best individual experience so patients can live their best lives. As part of that effort, we are integrating artificial intelligence (AI) across the research and development organization to bring accelerated solutions to patients with unmet needs. 

UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21. 

As part of Psoriasis Action Month, Camille Lee, Head of U.S. Immunology at UCB, shares how UCB is helping find and bridge gaps in psoriatic disease care. 

Today, UCB issued the following statement from Jeffrey Stark, M.D., Head of U.S. Medical Immunology, on the recent update by the ICD-10 Coordination and Maintenance Committee to endorse the creation of a new sub-category (M45.A) for non-radiographic axial spondyloarthritis (nr-axSpA). 

Congratulations to Anita Moser, Head of U.S. Neurology Assets and Optimization, and Erica Puntel, U.S. Neurology and Global Digital Business Transformation Communications Lead, for their recognition as Healthcare Businesswomen's Association (HBA) Rising Stars for 2021.

At UCB, we have come to develop a deep understanding of the patient experience and the unmet needs of people living with immuno-dermatological conditions. As we join for the American Academy of Dermatology VMX 2021 Conference, read from Rhonda Peebles, our Head of U.S. Dermatology, on UCB’s approach to creating value for patients.